Patents by Inventor Esther Maria FURRER

Esther Maria FURRER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TOPICAL TREATMENT OF INFLAMMATORY BOWEL DISEASE USING ANTIBODIES AND FRAGMENTS THEREOF
    Publication number: 20240000714
    Abstract: The present invention relates to the therapeutic uses of compositions containing antibody molecules and functional fragments thereof, e.g antibody molecules and functional fragments capable of binding to tumor necrosis factor alpha (TNF?), in the topical treatment of inflammatory bowel diseases, including Crohn's disease and ulcerative colitis.
    Type: Application
    Filed: June 12, 2023
    Publication date: January 4, 2024
    Applicants: Tillotts Pharma AG, University College London
    Inventors: Vipul YADAV, Abdul Waseh BASIT, Felipe José OLIVEIRA VARUM, Roberto Carlos BRAVO GONZALÉZ, Esther Maria FURRER
  • ANTIBODY VARIANTS
    Publication number: 20230295288
    Abstract: The present invention relates to antibodies which bind to TNF? and comprise a modified Fc region. The antibodies of the invention have improved resistance against proteolytic degradation and good effector functions and/or pharmacokinetic properties.
    Type: Application
    Filed: September 20, 2022
    Publication date: September 21, 2023
    Applicant: Tillotts Pharma AG
    Inventor: Esther Maria FURRER
  • ANTI-TNF-ALPHA-ANTIBODIES AND FUNCTIONAL FRAGMENTS THEREOF
    Publication number: 20230279091
    Abstract: The present invention relates to antibody molecules and functional fragments thereof, capable of binding to tumor necrosis factor alpha (TNF?), to processes for their production, and to their therapeutic uses.
    Type: Application
    Filed: October 3, 2022
    Publication date: September 7, 2023
    Applicant: Tillotts Pharma AG
    Inventors: Tea GUNDE, Sebastian MEYER, Esther Maria FURRER
  • ANTI-TNF-ALPHA-ANTIBODIES AND FUNCTIONAL FRAGMENTS THEREOF
    Publication number: 20230272059
    Abstract: The present invention relates to antibody molecules and functional fragments thereof, capable of binding to tumor necrosis factor alpha (TNF?), to processes for their production, and to their therapeutic uses.
    Type: Application
    Filed: August 18, 2022
    Publication date: August 31, 2023
    Applicant: Tillotts Pharma AG
    Inventors: Tea GUNDE, Sebastian Meyer, Esther Maria Furrer
  • Topical treatment of inflammatory bowel disease using antibodies and fragments thereof
    Patent number: 11717484
    Abstract: The present invention relates to the therapeutic uses of compositions containing antibody molecules and functional fragments thereof, e.g antibody molecules and functional fragments capable of binding to tumor necrosis factor alpha (TNF?), in the topical treatment of inflammatory bowel diseases, including Crohn's disease and ulcerative colitis.
    Type: Grant
    Filed: April 26, 2018
    Date of Patent: August 8, 2023
    Assignees: Tillotts Pharma AG, University College London
    Inventors: Vipul Yadav, Abdul Waseh Basit, Felipe José Oliveira Varum, Roberto Carlos Bravo Gonzaléz, Esther Maria Furrer
  • Antibody variants
    Patent number: 11472872
    Abstract: The present invention relates to antibodies which bind to TNF? and comprise a modified Fc region. The antibodies of the invention have improved resistance against proteolytic degradation and good effector functions and/or pharmacokinetic properties.
    Type: Grant
    Filed: September 11, 2018
    Date of Patent: October 18, 2022
    Assignee: Tillotts Pharma AG
    Inventor: Esther Maria Furrer
  • Anti-TNF-alpha-antibodies and functional fragments thereof
    Patent number: 11459383
    Abstract: The present invention relates to antibody molecules and functional fragments thereof, capable of binding to tumor necrosis factor alpha (TNF?), to processes for their production, and to their therapeutic uses.
    Type: Grant
    Filed: March 16, 2017
    Date of Patent: October 4, 2022
    Assignee: Tillotts Pharm AG
    Inventors: Tea Gunde, Sebastian Meyer, Esther Maria Furrer
  • TOPICAL TREATMENT OF IMMUNE CHECKPOINT INHIBITOR INDUCED DIARRHOEA, COLITIS OR ENTEROCOLITIS USING ANTIBODIES AND FRAGMENTS THEREOF
    Publication number: 20220119515
    Abstract: The present invention relates to the therapeutic topical use of compositions containing antibody molecules or functional fragments or derivatives specific to tumour necrosis factor alpha (TNF?), for treating or preventing immune checkpoint (ICP) inhibitor-induced adverse events.
    Type: Application
    Filed: December 6, 2019
    Publication date: April 21, 2022
    Applicant: Tillotts Pharma AG
    Inventors: Esther Maria FURRER, Felipe VARUM, Roberto BRAVO, Johannes SPLEISS, Marijana NEDELJKOVIC POTIC, Ortrud GERSTNER, Cristina BRUNO
  • ANTI-TNF-ALPHA-ANTIBODIES AND FUNCTIONAL FRAGMENTS THEREOF
    Publication number: 20210198353
    Abstract: The present invention relates to antibody molecules and functional fragments thereof, capable of binding to tumor necrosis factor alpha (TNF?), to processes for their production, and to their therapeutic uses.
    Type: Application
    Filed: March 16, 2017
    Publication date: July 1, 2021
    Applicant: Tillotts Pharma AG
    Inventors: Tea GUNDE, Sebastian MEYER, Esther Maria FURRER
  • Anti-TNF-?-antibodies and functional fragments thereof
    Patent number: 10975143
    Abstract: The present invention relates to antibody molecules and functional fragments thereof, capable of binding to tumor necrosis factor alpha (TNF?), to processes for their production, and to their therapeutic uses.
    Type: Grant
    Filed: March 16, 2017
    Date of Patent: April 13, 2021
    Assignee: Tillotts Pharma AG
    Inventors: Tea Gunde, Sebastian Meyer, Esther Maria Furrer
  • ANTI-TNF-ALPHA-ANTIBODIES AND FUNCTIONAL FRAGMENTS THEREOF
    Publication number: 20200299375
    Abstract: The present invention relates to antibody molecules and functional fragments thereof, capable of binding to tumor necrosis factor alpha (TNF?), to processes for their production, and to their therapeutic uses.
    Type: Application
    Filed: March 16, 2017
    Publication date: September 24, 2020
    Applicant: Tillotts Pharma AG
    Inventors: Tea GUNDE, Sebastian MEYER, Esther Maria FURRER
  • ANTIBODY VARIANTS
    Publication number: 20200277367
    Abstract: The present invention relates to antibodies which bind to TNF? and comprise a modified Fc region. The antibodies of the invention have improved resistance against proteolytic degradation and good effector functions and/or pharmacokinetic properties.
    Type: Application
    Filed: September 11, 2018
    Publication date: September 3, 2020
    Applicant: Tillotts Pharma AG
    Inventor: Esther Maria FURRER
  • ANTIBODY VARIANTS
    Publication number: 20200255511
    Abstract: The present invention relates to antibodies which bind to TNF? and exhibit modified FcRn-binding. The antibodies of the invention have good effector functions and/or pharmacokinetic properties.
    Type: Application
    Filed: September 11, 2018
    Publication date: August 13, 2020
    Inventor: Esther Maria FURRER
  • ANTIBODY VARIANTS
    Publication number: 20200216527
    Abstract: The present invention relates to antibodies which bind to TNF? and exhibit modified FcRn-binding. The antibodies of the invention have good effector functions and/or pharmacokinetic properties.
    Type: Application
    Filed: September 11, 2018
    Publication date: July 9, 2020
    Applicant: Tillotts Pharma AG
    Inventor: Esther Maria FURRER
  • TOPICAL TREATMENT OF INFLAMMATORY BOWEL DISEASE USING ANTIBODIES AND FRAGMENTS THEREOF
    Publication number: 20200170956
    Abstract: The present invention relates to the therapeutic uses of compositions containing antibody molecules and functional fragments thereof e.g antibody molecules and functional fragments capable of binding to tumor necrosis factor alpha (TNF?), in the topical treatment of inflammatory bowel diseases, including Crohn's disease and ulcerative colitis.
    Type: Application
    Filed: April 26, 2018
    Publication date: June 4, 2020
    Applicants: Tillotts Pharma AG, University College London
    Inventors: Vipul YADAV, Abdul Waseh BASIT, Felipe José OLIVEIRA VARUM, Roberto Carlos BRAVO GONZALÉZ, Esther Maria FURRER